Building on our previous research, this study further confirms that MSI2 can affect EMT by regulating NLK, and both of them together promote the deterioration of the prognosis of pancreatic cancer patients, which also provides a potential target for EMT-targeted therapy in pancreatic cancer. The gene discussed is MSI2; the disease is pancreatic neoplasm.